Company profile
Septerna Inc
NASDAQ: SEPN · Healthcare · Biotechnology
#445 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
51DFH 62DQ 33GM —SS 52
v0.1 · 55/100 weight · provisional
↑ revenue growth (YoY), market scale · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$98.9M
Rev growth YoY (TTM)
+13520.1%
Net income (FY)
-$48.9M
Employees
123
as of 2026-09-10
Market cap
$1.7B
as of 2026-09-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$46.0M$46.0M2025
Net income-$48.9M-$48.9M2025
Operating income-$68.3M-$68.3M2025
Total assets$596.2M$596.2M2025
Liabilities$214.3M$214.3M2025
Equity$381.9M$381.9M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Septerna Inc’s revenue?
Septerna Inc booked $46.0M in FY2025 revenue, growing 4175% year over year — faster than 99% of Healthcare companies we track, at a -106.4% net margin.
Peers · Healthcare
Shoulder Innovations, Inc.42DEvome Medical Technologies Inc.——Protagonist Therapeutics, Inc.57CTriSalus Life Sciences, Inc.44DFennec Pharmaceuticals Inc.61CAquestive Therapeutics, Inc.47DNeighbors
San Mateo →Key facts
CEOJeffrey T. Finer
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: SEPN
Employees123
IPO date2024-10-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.